Opin vísindi

Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis : A Set of Parallel Case-control Studies

Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis : A Set of Parallel Case-control Studies


Titill: Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis : A Set of Parallel Case-control Studies
Höfundur: Meer, Elana
Thrastardottir, Telma
Wang, Xingmei
Dubreuil, Maureen
Chen, Yong
Gelfand, Joel M.
Love, Thorvardur J.
Ogdie, Alexis
Útgáfa: 2022-01-01
Tungumál: Enska
Umfang: 7
Deild: Faculty of Medicine
Other departments
Birtist í: Journal of Rheumatology; 49(1)
ISSN: 0315-162X
DOI: 10.3899/jrheum.210006
Efnisorð: Gigtarlæknisfræði; ankylosing spondylitis; epidemiology; psoriasis; psoriatic arthritis; rheumatoid arthritis; risk factors; Psoriasis; Arthritis, Psoriatic/diagnosis; Humans; Risk Factors; Spondylitis, Ankylosing/diagnosis; Case-Control Studies; Arthritis, Rheumatoid/diagnosis; Rheumatology; Immunology and Allergy; Immunology
URI: https://hdl.handle.net/20.500.11815/3801

Skoða fulla færslu

Tilvitnun:

Meer , E , Thrastardottir , T , Wang , X , Dubreuil , M , Chen , Y , Gelfand , J M , Love , T J & Ogdie , A 2022 , ' Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis : A Set of Parallel Case-control Studies ' , Journal of Rheumatology , vol. 49 , no. 1 , pp. 53-59 . https://doi.org/10.3899/jrheum.210006

Útdráttur:

Objective. To compare potential risk factors for the diagnosis of psoriatic arthritis (PsA), psoriasis (PsO), rheumatoid arthritis (RA), and ankylosing spondylitis (AS). Methods. Four parallel case-control studies were conducted within The Health Improvement Network using data between 1994 and 2015. Patients with PsA, PsO, RA, or AS were identified using validated code lists and matched to controls on age, sex, practice, and year. Risk factors were selected in the time prior to diagnosis. Multivariable logistic regression models were constructed for each disease using automated stepwise regression to test potential risk factors. Results. Patients with incident PsA (n = 7594), PsO (n = 111,375), RA (n = 28,341), and AS (n = 3253) were identified and matched to 75,930, 1,113,345, 283,226, and 32,530 controls, respectively. Median diagnosis age was 48 (IQR 38–59), 43 (IQR 28–60), 60 (IQR 48–71), and 41 (IQR 32–54) years, respectively. In multivariable models, there were some shared and some differing risk factors across all 4 diseases: PsA was associated with obesity, pharyngitis, and skin infections; PsA and PsO were associated with obesity and moderate alcohol intake; PsA and AS were associated with uveitis; and PsA and RA were associated with preceding gout. Both RA and AS were associated with current smoking, former moderate drinking, anemia, osteoporosis, and inflammatory bowel disease. All shared former or current smoking as a risk factor; statin use was inversely associated with all 4 diseases. Conclusion. Shared and different risk factors for PsA, PsO, RA, and AS were identified. Statin use was inversely associated with all 4 conditions.

Athugasemdir:

Funding Information: This work was supported in part by the National Institutes of Health (NIH), Grant K23 AR063764, to the principal investigator AO, and internal funds from the University of Pennsylvania. MD was supported by the NIH, Grant K23 AR06912701. 1E. Meer, BA, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 2T. Thrastardottir, MPH, T.J. Love, MD, PhD, Department of Medicine/Rheumatology, University of Iceland and Landspitali, Reykjavik, Iceland; 3X. Wang, MD, Y. Chen, PhD, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 4M. Dubreuil, MD, Department of Medicine/Rheumatology, Boston University, Boston, Massachusetts, USA; 5J.M. Gelfand, MD, MSCE, Department of Biostatistics, Epidemiology and Informatics, and Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 6A. Ogdie, MD, MSCE, Department of Biostatistics, Epidemiology and Informatics, and Department of Medicine/ Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. JMG has served as a consultant for BMS, Boehringer Ingelheim, Lilly, Janssen Biologics, Novartis, UCB (DSMB), Neuroderm (DSMB), Dr. Reddy’s Labs, Pfizer, and Sun Pharma, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Boehringer Ingelheim, Janssen, Novartis, Celgene, Ortho Dermatologics, and Pfizer; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologics, and Novartis. JMG is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma, is a Deputy Editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology, and is a member of the Board of Directors for the International Psoriasis Council, receiving no honoraria. TJL has received reimbursement from Celgene for speaking about guidelines for the treatment of psoriatic arthritis. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Global Health Living Foundation, Janssen, Lilly, Novartis, Pfizer, and Takeda, and has received grants to the University of Pennsylvania from Pfizer and Novartis and to Forward from Amgen; her husband has received royalties from Novartis. EM, TT, MD, XW, and YC declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Ogdie, University of Pennsylvania, Division of Rheumatology, 3400 Civic Center Blvd., Philadelphia, PA 19104, USA. Email: alogdie@pennmedicine.upenn.edu. Accepted for publication July 16, 2021. Publisher Copyright: © 2022 The Journal of Rheumatology.

Skrár

Þetta verk birtist í eftirfarandi safni/söfnum: